Literature DB >> 11289474

Anemia with erythropoietin deficiency occurs early in diabetic nephropathy.

D R Bosman1, A S Winkler, J T Marsden, I C Macdougall, P J Watkins.   

Abstract

OBJECTIVE: The normochromic normocytic anemia of erythropoietin (EPO) deficiency is recognized in advanced renal failure but not in early renal disease. The aim of this study was to determine whether anemia with EPO deficiency is found in type 1 diabetic patients with diabetic nephropathy in the absence of advanced renal failure and to compare them with patients with nondiabetic renal disease of similar severity. RESEARCH DESIGN AND METHODS: A total of 27 type 1 diabetic patients with diabetic nephropathy (DN), defined as having persistent proteinuria (mean 1,086 mg/day [CI 120-5,1901), a serum creatinine < or = 180 micromol/l, and retinopathy, were compared with 26 nondiabetic patients with glomerulonephritis (GN) and persistent proteinuria (1,874 mg/day [349-5,005]). The Hb concentration, red cell indexes, and serum EPO levels were measured, and other causes for the anemia were excluded. The EPO values were compared with a normal reference range obtained from nondiabetic patients with a microcytic anemia. The DN patients were tested for signs of diabetic peripheral and autonomic neuropathy.
RESULTS: We found that 13 of the 27 DN patients were anemic (Hb 10.6 +/- 0.9 g/dl) in marked contrast to none of the GN patients (Hb 13.7 +/- 1.4 g/dl, P < 0.005). In the DN group, serum EPO concentrations failed to increase in response to anemia compared with the response seen in patients with microcytic anemia. Thus, the anemia of the DN group was associated with EPO deficiency. The anemic DN patients showed evidence of more severe proteinuria and diabetic neuropathy than the nonanemic DN patients.
CONCLUSIONS: Anemia associated with EPO deficiency can occur early in DN before the onset of advanced renal failure, but does not normally occur in nondiabetic renal disease of similar severity. The pathogenesis requires elucidation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289474     DOI: 10.2337/diacare.24.3.495

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  58 in total

1.  Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.

Authors:  Christi Hayes; Anis Alam; Julie Black-Peart; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

Review 2.  Anemia and diabetic nephropathy.

Authors:  Eberhard Ritz
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

3.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

4.  Prevalence of anaemia in patients with diabetes mellitus.

Authors:  T J Cawood; U Buckley; A Murray; M Corbett; D Dillon; B Goodwin; S Sreenan
Journal:  Ir J Med Sci       Date:  2006 Apr-Jun       Impact factor: 1.568

Review 5.  Anemia and cardiovascular disease in diabetic nephropathy.

Authors:  Samy I McFarlane; Moro O Salifu; John Makaryus; James R Sowers
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

6.  A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.

Authors:  G J S Cooper; A A Young; G D Gamble; C J Occleshaw; A M Dissanayake; B R Cowan; D H Brunton; J R Baker; A R J Phillips; C M Frampton; S D Poppitt; R N Doughty
Journal:  Diabetologia       Date:  2009-01-27       Impact factor: 10.122

Review 7.  Anaemia in diabetes: Is there a rationale to TREAT?

Authors:  M C Thomas; M E Cooper; K Rossing; H H Parving
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

Review 8.  Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

Authors:  Robert Deicher; Walter H Hörl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Anemia, diabetes, and chronic kidney disease.

Authors:  Uzma Mehdi; Robert D Toto
Journal:  Diabetes Care       Date:  2009-07       Impact factor: 17.152

10.  Association between diabetic retinopathy and hemoglobin level.

Authors:  Adele Bahar; Zahra Kashi; Ahmad Ahmadzadeh Amiri; Majid Nabipour
Journal:  Caspian J Intern Med       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.